




Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease

Antonio Vitale¹ · Giacomo Emmi² · Giuseppe Lopalco³ · Claudia Fabiani⁴ · Stefano Gentileschi¹ · Elena Silvestri² · Gerardo Di Scala² · Florenzo Iannone³ · Bruno Frediani¹ · Mauro Galeazzi¹ · Giovanni Lapadula³ · Donato Rigante⁵ · Luca Cantarini^{1,6} 

Published online: 22 September 2018

© International League of Associations for Rheumatology (ILAR) 2018

Correction to: *Clin Rheumatol* (2017) 36:2063–2069
<https://doi.org/10.1007/s10067-017-3627-4>

In the original version of this article the author name **Gerardo Di Scala** was originally presented incorrectly as '**Di Scala Gerardo**'; this has been corrected in this article.

The online version of the original article can be found at <https://doi.org/10.1007/s10067-017-3627-4>

✉ Claudia Fabiani
claudia.fabiani@gmail.com

✉ Luca Cantarini
cantariniluca@hotmail.com

¹ Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

² Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

³ Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

⁴ Department of Ophthalmology, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano, Milan, Italy

⁵ Institute of Pediatrics, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica Sacro Cuore, Rome, Italy

⁶ Rheumatology Unit, Policlinico "Le Scotte", University of Siena, viale Bracci 1, 53100 Siena, Italy